Related Experiment Video

Updated: Dec 3, 2025

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.5K

Influence of Cinnamon on Glycemic Control in Individuals With Prediabetes: A Randomized Controlled Trial

Giulio R Romeo1, Junhee Lee2,3, Christopher M Mulla1,4

  • 1Joslin Diabetes Center, Boston, Massachusetts, US.

Journal of the Endocrine Society
|October 30, 2020
PubMed
Abstract

Insights

Cinnamon supplementation in prediabetes improved fasting glucose and glucose tolerance over 12 weeks. This study suggests cinnamon as a safe, adjunctive approach to manage prediabetes and potentially reduce type 2 diabetes progression.

Area of Science:

  • Endocrinology
  • Metabolic Health
  • Nutritional Science

Background:

  • Prediabetes poses a significant risk for type 2 diabetes (T2D) development.
  • Effective, safe, and cost-efficient interventions to slow prediabetes progression are needed.
  • The glucose-lowering potential of cinnamon in prediabetic individuals remains largely unexplored.

Purpose of the Study:

  • To evaluate the efficacy of cinnamon supplementation in improving glucose homeostasis in individuals with prediabetes.
  • To assess the impact of cinnamon on fasting plasma glucose (FPG) and oral glucose tolerance test (OGTT) parameters.

Main Methods:

  • A 12-week, double-blind, placebo-controlled clinical trial.
  • 27 adult participants with prediabetes received 500 mg of cinnamon or placebo thrice daily.
  • Primary outcome: change in FPG; Secondary outcomes: changes in 2-hour PG and AUC from OGTT.

Main Results:

  • Fasting plasma glucose remained stable with cinnamon, while it increased with placebo (mean difference: 5 mg/dL, P < .05).
  • Cinnamon significantly reduced both 2-hour PG (P < .05) and AUC PG (P < .001) from baseline.
  • No serious adverse events were reported in either group, indicating a favorable safety profile.

Conclusions:

  • Twelve weeks of cinnamon supplementation demonstrated significant improvements in FPG and glucose tolerance in prediabetic individuals.
  • Cinnamon presents a safe adjunctive option for managing prediabetes.
  • Further research with larger cohorts and longer durations is warranted to investigate cinnamon's effect on T2D progression.
Keywords:
cinnamonglucose toleranceoxidative stressprediabetesprevention

More Related Videos

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet13:09

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

4.0K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

559

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
418
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
751
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
490
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
429
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
455